Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
PrEP
Pharma
NICE rebuffs Gilead's twice-yearly PrEP option
NICE is recommending against national coverage of Gilead Sciences’ landmark twice-a-year PrEP medication lenacapavir.
Fraiser Kansteiner
Sep 10, 2026 10:12am
Gilead's Yeztugo faces growth outlook questions
Aug 5, 2026 10:44am
Merck prepares expanded access to monthly PrEP pill early
Jul 24, 2026 10:40am
ViiV Healthcare launches ‘PrEP Wisdom’ campaign
Jun 1, 2026 9:45am
Gilead says long-acting PrEP Yeztugo in line for $1B in '26 sales
May 8, 2026 11:30am
Manufacturing is key to Gilead's Yeztugo PrEP rollout: exec
Mar 13, 2026 10:33am
